605177.SH
东亚药业
SSE · Healthcare · Biotechnology · CN
CNY 20.64
−0.43%Year over year
Reported trailing growth
- Revenue
- -2.2%
- EBITDA
- —
- EBIT
- +19.0%
- EPS
- +18.0%
- Free cash flow
- +62.5%
- Operating cash flow
- +47.3%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -7.3%
- EBITDA
- -30.7%
- EBIT
- +16.8%
- Net income
- +18.1%
- EPS
- +20.0%
- Free cash flow
- +6.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026